Assessment of Ankaferd Blood Stopper in experimental liver ischemia reperfusion injury

Authors: ABDULLAH DURHAN, KORAY KOŞMAZ, MARLEN SÜLEYMAN, MESUT TEZ, ABDULLAH ŞENLİKCİ, CAN ERSAK, YILMAZ ÜNAL, MEVLÜT RECEP PEKCİCİ, FATİH KARAAHMET, MEHMET ŞENEŞ, İLKNUR ALKAN KUŞABBİ, EYLEM PINAR ESER, SEMA HÜCÜMENOĞLU

Abstract: Background/aim: To investigate possible protective effects of Ankaferd Blood Stopper® (ABS) in an experimental liver ischemia reperfusion injury (IRI) model. Materials and methods: The study was carried out on 30 female rats separated into 3 groups as sham, control (IRI), and treatment (IRI + ABS) groups. In the IRI + ABS group, 0.5 mL/day ABS was given for 7 days before surgery. In the IRI and IRI + ABS groups, the hepatic pedicle was clamped for 30 min to apply ischemia. Then, after opening the clamp, 90-min reperfusion of the liver was provided. Blood and liver tissue samples were taken for biochemical and histopathological analyses.Results: Compared to the sham group, the IRI group had significantly higher levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), total oxidant status (TOS), malondialdehyde (MDA), fluorescent oxidant products (FOP) and lower expression of albumin and total antioxidant status (TAS) (P < 0.05). Compared to the IRI group, the IRI+ABS group showed lower expression of AST, ALT, TOS, MDA and FOP and higher expression of albumin and TAS (P < 0.05). In the histopathological analysis, congestion scores were statistically significantly lower in the IRI + ABS group than in the IRI group.Conclusions: ABS has a strong hepatoprotective effect due to its antioxidant and antiinflammatory effects and could therefore be used as a potential therapeutic agent for IRI.

Keywords: Ischemia reperfusion injury, Ankaferd Blood Stopper, liver

Full Text: PDF